New research shows that patients with psoriatic arthritis (PsA) have a greater risk for developing type 2 diabetes than patients with psoriasis alone or the general population. Researchers also found that PsA and psoriasis patients have a similar rate of increased risk for cardiovascular disease…
New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…
NEW YORK (Reuters Health)—Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn’s disease (CD), according to data from company-sponsored clinical trials. Adalimumab is an anti-tumor necrosis factor monoclonal antibody with demonstrated efficacy in these conditions, but pediatric safety data remains limited. Dr. Gerd…
The National Psoriasis Foundation says weight loss and other dietary interventions may benefit psoriasis patients. New recommendations note the benefits of a gluten-free diet for patients who test positive for gluten sensitivity, but also found little evidence to support the use of fish oil supplements for psoriasis patients…
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…
Ixekizumab is the first agent approved by the FDA for treating plaque psoriasis to include labeling for psoriasis in the genital area…
NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…
In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…
Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…
In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…